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Abstract
Background: Pleomorphic malignant fibrous histiocytoma (MFH) is one of the most frequent malignant soft tissue
tumors in adults. Despite the considerable amount of research on MFH cell lines, their characterization at a
molecular cytogenetic level has not been extensively analyzed.
Methods and results: We established a new permanent human cell line, FU-MFH-2, from a metastatic
pleomorphic MFH of a 72-year-old Japanese man, and applied multicolor fluorescence in situ hybridization (M-
FISH), Urovysion™ FISH, and comparative genomic hybridization (CGH) for the characterization of chromosomal
aberrations. FU-MFH-2 cells were spindle or polygonal in shape with oval nuclei, and were successfully maintained
in vitro for over 80 passages. The histological features of heterotransplanted tumors in severe combined
immunodeficiency mice were essentially the same as those of the original tumor. Cytogenetic and M-FISH analyses
displayed a hypotriploid karyotype with numerous structural aberrations. Urovysion™ FISH revealed a homozygous
deletion of the p16
INK4A locus on chromosome band 9p21. CGH analysis showed a high-level amplification of
9q31-q34, gains of 1p12-p34.3, 2p21, 2q11.2-q21, 3p, 4p, 6q22-qter, 8p11.2, 8q11.2-q21.1, 9q21-qter, 11q13, 12q24,
15q21-qter, 16p13, 17, 20, and X, and losses of 1q43-qter, 4q32-qter, 5q14-q23, 7q32-qter, 8p21-pter, 8q23,
9p21-pter, 10p11.2-p13, and 10q11.2-q22.
Conclusion: The FU-MFH-2 cell line will be a particularly useful model for studying molecular pathogenesis of
human pleomorphic MFH.
Background
Pleomorphic malignant fibrous histiocytoma (MFH),
also known as undifferentiated high grade pleomorphic
sarcoma, is among the most common adult soft tissue
sarcomas, but the precise histogenesis of this tumor is
controversial [1]. Pleomorphic MFH frequently shows
highly aggressive behavior, resistance to radiotherapy
and chemotherapy, and fatal metastasis.
Well-characterized human sarcoma cell lines are valu-
able resources for developing new strategies against
sarcoma cell growth and progression. Although a num-
ber of human cell lines derived from MFH have been
reported [2-17], their characterization at the molecular
cytogenetic level has been limited. Here, we describe the
development of a new human cell line, designated as
FU-MFH-2, derived from a metastatic pleomorphic
MFH. In addition, we investigate genomic alterations in
FU-MFH-2 by a combination of molecular cytogenetic
techniques.
Methods
Source of tumor cells
The original tumor tissue specimen was surgically
obtained from a metastatic pleomorphic MFH of the left
* Correspondence: jnishio@cis.fukuoka-u.ac.jp
1Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka
University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan
Full list of author information is available at the end of the article
Nishio et al. Journal of Experimental & Clinical Cancer Research 2010, 29:153
http://www.jeccr.com/content/29/1/153
© 2010 Nishio et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.thigh in a 72-year-old Japanese man (Figure 1). One
year earlier, a left lower leg tumor was resected and a
histological diagnosis of pleomorphic MFH was estab-
lished. Immunohistochemically, the tumor cells were
frequently positive for vimentin and focally for CD68
and lysozyme. The other antibodies tested were nega-
tive. The patient died of lung metastasis 2 years after
the initial diagnosis.
Establishment of cell line and determination of cell
population doubling time
Fresh tumor tissue was minced with fine scissors and
then digested with 200 IU/ml type II collagenase
(Worthington Biochemical Corporation, Freehold, NJ,
USA) in serum-free medium for 30 minutes at 37°C.
After digestion, isolated cells were washed and seeded in
a 25-cm
2 plastic flask (Falcon 3013, Becton Dickinson
Japan, Tokyo, Japan) containing culture medium, and
maintained in a humidified atmosphere of 5% CO2 in
air at 37°C. The culture medium was composed of a 1:1
mixture of Dulbecco’s Modified Eagle Medium (DMEM)
and Ham’sF - 1 2( G I B C OB R L ,G r a n dI s l a n d ,N Y ,U S A )
supplemented with 10-20% fetal calf serum (FCS; Cell
Culture Laboratories, Cleveland, OH, USA) and kana-
mycin sulfate (100 μg/ml; Meiji Seika, Tokyo, Japan).
The medium was replaced twice weekly. When
Figure 1 Histologic appearance of the original tumor showing atypical spindle cells, polygonal cells, and bizarre giant cells,
corresponding to pleomorphic MFH.
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Page 2 of 10semi-confluent layers were obtained, the cells were dis-
persed with phosphate buffered saline (PBS) containing
0.1% trypsin and 0.02% ethylenediamine tetraacetic acid
(EDTA) solution and seeded in new flasks for passage.
These procedures were serially performed until estab-
lishment of the FU-MFH-2 cell line.
To determine the doubling time, 1.0 × 10
5 FU-MFH-2
cells/cm
2 at passage 31 were seeded in each well of 24-well
dishes (Corning Costar, Tokyo, Japan) with fresh medium
containing 1 ml of DMEM/F-12 with 10% FCS. The cul-
ture dishes were harvested, and then the number of viable
cells in each dish was counted by the dye exclusion test
(0.1% trypan blue in PBS) every 24 hours for 7 days.
Tumorigenicity in severe combined immunodeficiency
(SCID) mice
To determine the tumorigenicity of the FU-MFH-2 cell
line in vivo,5×1 0
7 cells at passage 23 were washed,
suspended in PBS, and injected subcutaneously into the
back of two 5-week-old female athymic SCID mice
(CB-17/Icr-scid; Jcl Clea Japan, Inc., Osaka, Japan). The
mice were maintained in a pathogen-free environment
and carefully observed after transplantation. The experi-
mental protocol was approved by the Ethics Review
Committee for Animal Experimentation of Fukuoka
University Faculty of Medicine.
Pathologic studies
The cells grown in culture flasks were observed by
phase-contrast microscopy. FU-MFH-2 cells at passages
31 and 42 were examined. For routine light microscopy,
the cells cultured in chamber slides (Lab-Tek, Miles
Laboratories, Naperville, IL, USA) were fixed in metha-
nol and stained with hematoxylin and eosin (H&E) and
Giemsa. Paraffin sections from the original tumor and
xenografts were stained with the same reagents. The pri-
mary antibodies and their dilutions used for immunocy-
tochemistry are listed in Table 1. The cells grown in
chamber slides were washed in PBS and fixed in cold
acetone for 5 minutes. The cells were reacted with each
of the primary antibodies for 1 hour at room tempera-
ture. The bound antibodies were then visualized using a
labeled streptavidin biotin system and the alkaline phos-
phatase technique, as described previously [15]. Paraffin
sections from the original tumor and xenografts were
also examined using the same procedure.
Cytogenetic analysis
The FU-MFH-2 cells at passages 25 and 52 and the
fresh original tumor cells were used for cytogenetic ana-
lysis. Metaphase cells were banded with Giemsa trypsin,
and karyotypic descriptions were done according to the
International System for Human Cytogenetic Nomencla-
ture 2009 [18].
Multicolor fluorescence in situ hybridization (M-FISH) and
Urovysion™ FISH
Multicolor and multitarget FISH studies were performed
on unstained cytogenetic preparations utilizing a com-
mercially available M-FISH probe kit (24XCyte, Meta-
Systems GmbH, Altlusheim, Germany) and the
Urovysion™ FISH probe mixture (Abbott Molecular, Des
Plaines, IL, USA) containing a specific probe for the
locus 9p21 (Spectrum Gold) and three alpha-satellite
centromere-specific probes for chromosomes 3 (Spec-
trum Red), 7 (Spectrum Green), and 17 (Spectrum
Aqua), respectively. The cells and probes were codena-
tured at 72°C for 2 minutes and subsequently placed in
a moist chamber for at least two nights at 37°C. Post-
hybridization washing was performed as previously
described with minor modifications [19,20]. The slides
were air-dried in the dark and counterstained with 4’,6-
diamidino-2-phenylindole (DAPI II; Abbott Molecular).
Image processing and 24-color karyotyping were per-
formed with the SpectraVysion Imaging System (Abbott
Molecular). Hybridization signals were assessed in a
minimum of 10 metaphase cells.
DNA extraction and Comparative genomic
hybridization (CGH)
DNA was extracted from FU-MFH-2 cells at passage 25
and from the original tumor tissue according to a stan-
dard procedure using phenol and chloroform extraction
followed by ethanol precipitation. The purity and mole-
cular weight of DNA were estimated using ethidium
bromide-stained agarose gels.
Table 1 Antibodies used in the present study
Antibody Type Source Dilution
Vimentin M Dakopatts, Kyoto, Japan 1:50
EMA M Dakopatts 1:50
AE1/AE3 M Dakopatts 1:50
CAM 5.2 M Becton Dickinson, San Jose, CA, USA 1:50
Desmin M Dakopatts 1:50
a-SMA M Dakopatts 1:50
MSA
(HHF35)
M Enzo Diagnostics, Farmingdale, NY, USA 1:50
S-100
protein
P Dakopatts 1:1000
NSE M Dakopatts 1:200
CD68 (KP-1) M Dakopatts 1:200
Lysozyme P Dakopatts 1:500
AAT P Dakopatts 1:1000
ACT P Dakopatts 1:1000
C-Kit P Immuno-Biological Laboratories, Fujioka,
Japan
1:10
Abbreviations: EMA, epithelial membrane antigen; a-SMA, alpha-smooth
muscle actin; MSA, muscle-specific actin; NSE, neuron-specific enolase; AAT,
alpha-1-antitrypsin; ACT, alpha-1-antichymotrypsin; M, monoclonal (mouse);
P, polyclonal (rabbit).
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Briefly, DNA from the FU-MFH-2 cell line and original
tumor was directly labeled with fluorescein-12-dUTP
(Roche Diagnostics, Mannheim, Germany) by nick trans-
lation, with the use of a commercial kit (Abbott Molecu-
lar). As a normal reference DNA, we used the Spectrum
Red directed-labeled male total human DNA (Abbott
Molecular). Subsequently, equal amounts of normal and
tumor labeled probes (400 ng) and 20 μgo fC o t - 1D N A
(GIBCO BRL) were coprecipitated with ethanol. The pre-
cipitated DNA was dissolved in 10 μlo fh y b r i d i z a t i o n
buffer and denatured at 75°C for 8 minutes. Normal
metaphase spreads (Abbott Molecular) were denatured
for 3 minutes at 75°C and hybridized with the DNA mix-
ture in a moist chamber for 3 days. Slides were washed
according to the protocol supplied by the manufacturer.
Chromosomes were counterstained with 4’,6-diamino-2-
phenylindole (DAPI; Sigma, St. Louis, MO, USA) and
embedded in antifade solution (Vectashield, Vector
Laboratories, Burlingame, CA, USA).
Digital image analysis
The location of aberrant CGH signals was analyzed using
an image analysis system (Isis, Carl Zeiss Vision, Oberko-
chen, Germany) based on an integrated high-sensitivity
monochrome charge-coupled device camera and auto-
mated CGH analysis software (MetaSystems GmbH).
Three-color images, green (fluorescein-12-dUTP) for the
tumor DNA, red (Spectrum Red) for the reference DNA,
and blue (DAPI) for the DNA counterstain, were acquired
from at least 10 metaphases. Only metaphases of good
quality with strong, uniform hybridization were included
in the analysis. Based on the control experiments, 1.2 and
0.8 were used as cutoff levels for gains and losses, respec-
tively. Gains exceeding the 1.5 threshold were termed
high-level amplifications. The heterochromatic regions in
chromosomes 1, 9, and 16, the p-arms of the acrocentric
chromosomes, and Y chromosome were excluded from
the analysis because of suppression of hybridization with
Cot-1 DNA in these regions.
Results
Establishment of FU-MFH-2 cell line and doubling time
Four weeks after initial cultivation in primary culture,
spindle-shaped, round, or polygonal tumor cells reached
sub-confluence with some piled-up foci of cells. These
cells were collected after a 5-minute digestion at 37°C
with a 0.1% trypsin solution, and replated in two 25-cm
2
plastic flasks containing fresh medium. Once confluent
they were serially subcultured at a dilution of 1:2.
Approximately 2 months later, at passages 4 to 5, the
cells began to grow rapidly, and thereafter could be seri-
ally subcultured at a dilution of 1:2 every week. This
new cell line was designated FU-MFH-2, and has been
maintained in vitro for more than 80 passages (a period
of more than 12 months). The population-doubling time
of FU-MFH-2 cells in logarithmic growth phase was
approximately 56 hours.
Tumor formation in vivo
Small elastic hard nodules became palpable in all SCID
mice at approximately 4 weeks after inoculation of FU-
MFH-2 cells. Two months later, the tumors had grown
up to 2.2 cm in diameter. The cut surfaces of these
tumors were solid and white with no secondary changes.
The mice were sacrificed humanely, and no metastatic
lesions were identified at autopsy.
Morphologic characterization in vitro and in vivo
As assessed by light microscopy, FU-MFH-2 cells
growing in chamber slides were spindle-shaped, round
or polygonal with extended slender cytoplasmic pro-
cesses. The cells proliferated loosely or in a storiform
pattern accompanied by irregularly piled up foci. The
nuclei were oval with distinct nucleoli (Figure 2A). As
shown by immunocytochemistry (Table 2), these cells
were positive for vimentin (Figure 2B) and CD68 (Fig-
ure 2C). The other antibodies tested in vitro were
negative. On the other hand, the histological features
of the heterotransplanted tumors were essentially simi-
lar to those of the original tumor. Namely, the tumors
were composed of a mixture of atypical spindle cells,
round cells, and bizarre giant cells arranged in a stori-
form pattern (Figure 3). Mitotic figures were frequently
found. Immunohistochemic a l l y( T a b l e2 ) ,t h et u m o r
cells were positive for vimentin and focally for CD68,
but were negative for the other antibodies tested in
vivo.
Cytogenetic findings
A representative karyotype is shown in Figure 4. FU-
MFH-2 displayed a highly complex karyotype with
numerous marker chromosomes. The composite karyo-
type was as follows: 55-61,XY,-X,add(X)(p22.1),add(1)
(q11),der(1)add(1)(p13)del(1)(q42),-2,-2,add(2)(p11.1), -3,
add(3)(q21),-4,add(4)(q31.1),-5,add(5)(q11.1),del(6)(q11)
× 2,del(7)(p11.1), del(7)(q11.1),der(7)add(7)(p22)add(7)
(q22),-8,add(9)(p11) × 2, der(9)del(9)(p11)add(9)(q22),-
10,add(10)(p13),-11,add(11)(q23),-12,-13,-14,add(14)
(p11.1),add(15)(p11.1),add(15)(p11.1),-17,-17,-18,-19,-20,
add(20)(q13.1),+add(21)(p11.1),-22,-22, +mar1,+mar2,
+mar3,+mar4,+mar5,+mar6,+mar7,+mar8,+mar9,+mar10,
+mar11,+mar12 [cp20]. Precisely the same karyotype was
recognized in the original tumor cells (data not shown).
Molecular cytogenetic findings
An M-FISH analysis identified 19 structural rearrange-
ments in the FU-MFH-2 cell (Figure 5). Chromosomes
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rearrangements.
Urovysion™ FISH revealed homozygous deletions of
the 9p21 locus containing the tumor suppressor gene
p16
INK4A in all analyzed metaphase and interphase cells
(Figure 6).
CGH analysis showed similar profiles in the original
tumor and FU-MFH-2 cell line. A high-level amplifica-
tion of 9q31-q34 was observed. Significant gains of
DNA sequences were detected in the 1p12-p34.3, 2p21,
2q11.2-q21, 3p, 4p, 6q22-qter, 8p11.2, 8q11.2-q21.1,
9q21-qter, 11q13, 12q24, 15q21-qter, 16p13, 17, 20, and
X regions. Significant losses of DNA sequences were
detected in the 1q43-qter, 4q32-qter, 5q14-q23, 7q32-
qter, 8p21-pter, 8q23, 9p21-pter, 10p11.2-p13, and
10q11.2-q22 regions. This CGH profile is represented in
Figure 7.
Discussion
We established the FU-MFH-2 cell line derived from
human pleomorphic MFH and used various analytical
methods to characterize this cell line. FU-MFH-2 cells
exhibited a spindle and polygonal shape, similar to other
pleomorphic MFH cell lines established previously
[5,13,15]. The immunophenotype of FU-MFH-2 cells in
vitro and in vivo was similar to that of the original
tumor cells. In addition, FU-MFH-2 cells could grow
in vivo to produce tumors with histopathologic features
similar to those of the original tumor in SCID mice.
Furthermore, FU-MFH-2 and the original tumor had
the same DNA sequence copy number changes by
CGH. These findings suggested that this cell line has
retained the characteristics of the original tumor.
Cytogenetic analyses of pleomorphic MFH have
revealed highly complex karyotypes lacking specific
structural or numerical aberrations [1,22]. Recurrent
breakpoints are seen in chromosome bands 1p36, 1q11,
1q21, 3p12, 11p11, 17p11, and 19p13 [23-25].
Figure 2 Light microscopic findings of FU-MFH-2 cells in vitro.
(A) FU-MFH-2 cells are spindle, round or polygonal in shape with
oval nuclei and extension of slender cytoplasmic processes. Most
FU-MFH-2 cells exhibit immunopositive reaction for vimentin (B)
and CD68 (C).
Table 2 Reactivity of FU-MFH-2 cells, in vitro and in vivo,
including the original tumor cells with various antibodies
Antibody FU-MFH-2 cells Original tumor cells
in vitro in vivo
Vimentin + + + + + + + + +
EMA - - -
AE1/AE3 - - -
CAM 5.2 - - -
Desmin - - -
a-SMA - - -
MSA - - -
S-100 protein - - -
NSE - - -
CD68 + + + + + + +
Lysozyme - - +
AAT - - -
ACT - - -
C-Kit - - -
Abbreviations: EMA, epithelial membrane antigen; a-SMA, alpha-smooth
muscle actin; MSA, muscle-specific actin; NSE, neuron-specific enolase;
AAT, alpha-1-antitrypsin; ACT, alpha-1-antichymotrypsin.
+ + +, > 75% positive cells; + +, 15-75% positive cells; +, < 15% positive cells,
-, negative reaction.
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types with a number of numerical and structural altera-
tions, including marker chromosomes. Using M-FISH
analysis, we were able to decipher the origin of marker
chromosomes and complex chromosomal rearrange-
ments. These results emphasize the usefulness of M-
FISH in the description of complex changes occurring
in pleomorphic MFH cell lines.
CGH studies have indicated that chromosomal gains
seem to be more frequent than losses in pleomorphic
MFH. Genomic imbalances frequently include gains of
1p31, 5p, 6q22-q24, 7q32, 9q31-q34, 12q13-q15, and
17q and losses of 9p21-pter and 13q14-q21 [26-30]. The
FU-MFH-2 cells also had gains of 1p12-p34.3, 6q22-
qter, 9q21-qter, and 17 and loss of 9p21-pter. Moreover,
a high-level amplification at 9q31-q34 was detected in
FU-MFH-2 cells, suggesting a critical role in pleo-
morphic MFH progression. Interestingly, Tarkkanen et
al. reported that gain of 9q32-qter was one of the most
frequent genomic imbalances in MFH of bone [31]. Sev-
eral candidate genes have been mapped to this chromo-
somal region, including VAV2, ABL1, Notch1,a n d
Tenascin-C (TNC). VAV2 is the second member of the
VAV guanine nucleotide exchange factor family of
oncogenes and is frequently gained in uterine leiomyo-
sarcoma [32]. Translocation-mediated transcriptional
activation of tyrosine kinase gene ABL1 is implicated in
the pathogenesis of chronic myeloid leukemia. Notch1
encodes a member of the Notch family and is a trans-
membrane receptor including an extracellular domain
Figure 3 Light microscopic finding of FU-MFH-2 cells in vivo.A
representative portion of the tumor in a SCID mouse, essentially
resembling the original tumor.
Figure 4 A representative G-banded karyotype of a metaphase FU-MFH-2 cell, including 12 marker chromosomes. Arrows indicate the
structural chromosome aberrations.
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Page 6 of 10Figure 5 Multicolor FISH of FU-MFH-2 cell line. Aberrant chromosomes are displayed in classified color image.
Figure 6 Multitarget FISH analysis performed on metaphase cells of FU-MFH-2 cell line with the Urovysion™ probe set reveals loss of
gold signals indicating homozygous deletions of the 9p21 locus. Centromeric signals (arrows) of chromosomes 3 (red), 7 (green), and 17
(aqua) are shown.
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repeats and an intracellular domain consisting of multi-
ple, different domain types. The Notch signaling path-
way is involved in a variety of cellular differentiation,
proliferation, and apoptosis [33]. Enjin et al. reported
that human osteosarcoma cell lines and primary human
osteosarcoma tumor samples showed significant upregu-
lation of Notch1 [34]. TNC is an oligomeric glycoprotein
of the extracellular matrix that is involved in embryo-
genesis, tumorigenesis, and angiogenesis. Of note, Fran-
chi et al. reported that TNC expression was found in
MFH [35]. However, the role of these genes in the
development and progression of pleomorphic MFH is
unknown.
The p16
INK4A gene is located at 9p21. This gene is fre-
quently mutated or deleted in a variety of tumors and is
known to be an important tumor suppressor gene [36].
Frequent deletions of p16
INK4A have also been reported in
pleomorphic MFH [37]. However, the association between
p16
INK4A alterations and prognosis in pleomorphic MFH
patients remains controversial [1]. In the present study, we
decided to examine this gene using metaphase FISH analy-
sis because loss of 9p21-pter was detected by CGH. As
expected, homozygous deletion of p16
INK4A was observed
in FU-MFH-2 cell line. Taken together, these findings sug-
gest that inactivation of p16
INK4A by homozygous deletion
may be important for pleomorphic MFH development,
although not tumor-type specific.
Conclusion
We described the establishment and characterization of
a new permanent human cell line, FU-MFH-2, derived
from a metastatic pleomorphic MFH. The FU-MFH-2
will be useful for various biologic and molecular patho-
genetic studies of human pleomorphic MFH.
Acknowledgements
This work was supported in part by Kaibara Morikazu Medical Science
Promotion Foundation, Japan Orthopaedics and Traumatology Foundation,
Fukuoka Cancer Society, Clinical Research Foundation, and a Grant-in-Aid for
Figure 7 CGH profile of FU-MFH-2 cell line showing high-level amplification of 9q31-q34, gains of 1p12-p34.3, 2p21, 2q11.2-q21, 3p,
4p, 6q22-qter, 8p11.2, 8q11.2-q21.1, 9q21-qter, 11q13, 12q24, 15q21-qter, 16p13, 17, 20, and X, and losses of 1q43-qter, 4q32-qter,
5q14-q23, 7q32-qter, 8p21-pter, 8q23, 9p21-pter, 10p11.2-p13, and 10q11.2-q22. The line in the middle (gray) is the baseline ratio (1.0);
the left (red) and right (green) lines indicate ratio values of 0.8 and 1.2, respectively. Bars to the left (red) and right (green) of each frame indicate
losses and gains, respectively. The terminology 1(10) represents 10 aberrations detected on chromosome 1. The same applies to other
chromosomes shown in the profile.
Nishio et al. Journal of Experimental & Clinical Cancer Research 2010, 29:153
http://www.jeccr.com/content/29/1/153
Page 8 of 10Young Scientists (B) (21791424) from the Ministry of Education, Culture,
Sports, Science and Technology of Japan.
Author details
1Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka
University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
2Department of Pathology, Faculty of Medicine, Fukuoka University, 7-45-1
Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
3Department of Orthopaedic
Surgery, Yanagawa Rehabilitation Hospital, 113-2 Kamimiyanaga-Machi,
Yanagawa City, Fukuoka 832-0058, Japan.
Authors’ contributions
JN conceived the study and drafted the manuscript. JN and MI carried out
the experimental work. TI managed the patient. HI, KN, TI, and MN
participated in the design of the study and evaluated the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 3 November 2010 Accepted: 24 November 2010
Published: 24 November 2010
References
1. Fletcher CDM, van den Berg E, Molenaar WM: Pleomorphic malignant
fibrous histiocytoma/undifferentiated high grade pleomorphic sarcoma.
In WHO Classification of Tumours, Pathology and Genetics of Tumours of Soft
Tissue and Bone. Edited by: Fletcher CDM, Unni KK, Mertens F. IARC Press:
Lyon, France; 2002:120-122.
2. Shirasuna K, Sugiyama M, Miyazaki T: Establishment and characterization
of neoplastic cells from a malignant fibrous histiocytoma. A possible
stem cell line. Cancer 1985, 55:2521-2532.
3. Roholl PJ, Kleyne J, Van Blokland M, Spies PL, Rutgers DH, Albus-Lutter CE,
Van Unnik JA: Characterization of two cell lines, derived from two
malignant fibrous histiocytomas. J Pathol 1986, 150:103-112.
4. Kanzaki T, Kitajima S, Suzumori K: Biological behavior of cloned cells of
human malignant fibrous histiocytoma in vivo and in vitro. Cancer Res
1991, 51:2133-2137.
5. Iwasaki H, Isayama T, Ohjimi Y, Kikuchi M, Yoh S, Shinohara N, Yoshitake K,
Ishiguro M, Kamada N, Enjoji M: Malignant fibrous histiocytoma: a tumor
of facultative showing mesenchymal differentiation in culture cell lines.
Cancer 1992, 69:437-447.
6. Yonemoto T, Takenouchi T, Tokita H, Tatezaki S, Mukaida N, Mikata A,
Moriya H: Establishment and characterization of a human malignant
fibrous histiocytoma cell line. Clin Orthop Relat Res 1995, 320:159-167.
7. Krause AK, Hinrichs SH, Orndal C, DeBoer J, Neff JR, Bridge JA:
Characterization of a human myxoid malignant fibrous histiocytoma cell
line, OH931. Cancer Genet Cytogenet 1997, 94:138-143.
8. Endo K, Sakatani T, Watanabe M, Yoshida H, Nanba E, Ito H: Wild-type p53
gene transfer resulted in cell cycle arrest, but not apoptosis of newly
established human malignant fibrous histiocytoma cell line. Int J Oncol
1999, 15:935-942.
9. Reinecke P, Moll R, Hildebrandt B, Schmitz M, Schneider EM, Koldovsky P,
Schardt C, Gabbert HE, Gerharz C: A novel human malignant fibrous
histiocytoma cell line of the heart (MFH-H) with secretion of
hematopoietic growth factor. Anticancer Res 1999, 19:1901-1907.
10. Mairal A, Chibon F, Rousselet A, Couturier J, Terrier P, Aurias A:
Establishment of a human malignant fibrous histiocytoma cell line,
COMA: characterization by conventional cytogenetics, comparative
genomic hybridization, and multiflex fluorescence in situ hybridization.
Cancer Genet Cytogenet 2000, 121:117-123.
11. Kiyozuka Y, Nakagawa H, Uemura Y, Senzaki H, Yamamoto A, Noguchi T,
Mizuta H, Nakanishi K, Nakano S, Tsubura A: Novel cell lines established
from a human myxoid malignant fibrous histiocytoma arising in the
uterus. Cancer Genet Cytogenet 2001, 27:7-15.
12. Mori A, Tagawa T, Kamei T, Murata T, Inui M, Ohse S: Characterization of
four cell lines derived from a human malignant fibrous histiocytoma of
the maxillary sinus. Oral Oncol 2001, 37:527-536.
13. Nakatani T, Marui T, Yamamoto T, Kurosaka M, Akisue T, Matsumoto K:
Establishment and characterization of cell line TNMY1 derived from
human malignant fibrous histiocytoma. Pathol Int 2001, 51:595-602.
14. Fang Z, Mukai H, Nomura K, Shinomiya K, Matsumoto S, Kawaguchi N,
Kitagawa T, Kanda H: Establishment and characterization of a cell line
from a malignant fibrous histiocytoma of bone developing in a patient
with multiple fibrous dysplasia. J Cancer Res Clin Oncol 2002, 128:45-49.
15. Nishio J, Iwasaki H, Ishiguro M, Ohjimi Y, Nishimura N, Koga T,
Kawarabayashi T, Kaneko Y, Kikuchi M: Establishment of a new human
malignant fibrous histiocytoma cell line, FU-MFH-1: cytogenetic
characterization by comparative genomic hybridization and fluorescence
in situ hybridization. Cancer Genet Cytogenet 2003, 144:44-51.
16. Kawashima H, Ogose A, Gu W, Nishio J, Kudo N, Kondo N, Hotta T,
Umezu H, Tohyama T, Nishijima H, Iwasaki H, Endo N: Establishment and
characterization of a novel myxofibrosarcoma cell line. Cancer Genet
Cytogenet 2005, 161:28-35.
17. Hakozaki M, Hojo H, Sato M, Tajino T, Yamada H, Kikuchi S, Abe M:
Establishment and characterization of a new cell line, FPS-1, derived
from human undifferentiated pleomorphic sarcoma, overexpressing
epidermal growth factor receptor and cyclooxygenase-2. Anticancer Res
2006, 26:3393-3402.
18. Shaffer LG, Slovak ML, Campbell LJ: ISCN. An international system for
human cytogenetic nomenclature. Basel: Karger 2009.
19. Ishiguro M, Iwasaki H, Takeshita M, Hirose Y, Kaneko Y: A cyotogetic
analyses in two cases of malignant peripheral nerve sheath tumor
showing hypodiploid karyotype. Oncol Rep 2006, 16:225-232.
20. Nishio J, Althof PA, Bailey JM, Zhou M, Neff JR, Barr FG, Parham DM, Teot L,
Qualman SJ, Bridge JA: Use of a novel FISH assay on paraffin-embedded
tissues as an adjunct to diagnosis of alveolar rhabdomyosarcoma. Lab
Invest 2006, 86:547-556.
21. Nishio J, Iwasaki H, Ohjimi Y, Ishiguro M, Isayama T, Naito M, Iwashita A,
Kikuchi M: Overrepresentation of 17q22-qter and 22q13 in
dermatofibrosarcoma protuberans but not in dermatofibroma: a
comparative genomic hybridization study. Cancer Genet Cytogenet 2002,
132:102-108.
22. Iwasaki H, Nabeshima K, Nishio J, Jimi S, Aoki M, Koga K, Hamasaki M,
Hayashi H, Mogi A: Pathology of soft-tissue tumors: daily diagnosis,
molecular cytogenetics and experimental approach. Pathol Int 2009,
59:501-521.
23. Rydholm A, Mandahl N, Heim S, Kreicbergs A, Willen H, Mitelman F:
Malignant fibrous histiocytoma with a 19p+ marker chromosome have
increased relapse rate. Genes Chromosomes Cancer 1990, 2:296-299.
24. Choong PFM, Mandahl N, Mertens F, Willen H, Alvegard T, Kreicbergs A,
Mitelman F, Rydholm A: 19p+ marker chromosome correlates with
relapse in malignant fibrous histiocytoma. Genes Chromosomes Cancer
1996, 16:88-93.
25. Schmidt H, Körber S, Hinze R, Taubert H, Meye A, Würl P, Holzhausen HJ,
Dralle H, Rath FW: Cytogenetic characterization of ten malignant fibrous
histiocytomas. Cancer Genet Cytogenet 1998, 100:134-142.
26. Larramendy ML, Tarkkanen M, Blomqvist C, Virolainen M, Wiklund T, Asko-
Seljavaara S, Elomaa I, Knuutila S: Comparative genomic hybridization of
malignant fibrous histiocytoma reveals a novel prognostic marker. Am J
Pathol 1997, 151:1153-1161.
27. Mairal A, Terrier P, Chibon F, Sastre X, Lecesne A, Aurias A: Loss of
chromosome 13 is the most frequent genomic imbalance in malignant
fibrous histiocytomas. A comparative genomic hybridization analysis of
a series of 30 cases. Cancer Genet Cytogenet 1999, 111:134-138.
28. Hinze R, Schagdarsurengin U, Taubert H, Meye A, Wurl P, Holzhausen HJ,
Rath FW, Schmidt H: Assessment of genomic imbalances in malignant
fibrous histiocytomas by comparative genomic hybridization. Int J Mol
Med 1999, 3:75-79.
29. Weng WH, Ahlen J, Lui WO, Brosjo O, Pang ST, Von Rosen A, Auer G,
Larsson O, Larsson C: Gain of 17q in malignant fibrous histiocytoma is
associated with a longer disease-free survival and a low risk of
developing distant metastasis. Br J Cancer 2003, 89:720-726.
30. Carneiro A, Francis P, Bendahl PO, Fernebro J, Akerman M, Fletcher C,
Rydholm A, Borg A, Nilbert M: Indistinguishable genomic profiles and
shared prognostic markers in undifferentiated pleomorphic sarcoma and
leiomyosarcoma: different sides of a single coin? Lab Invset 2009,
89:668-675.
31. Tarkkanen M, Larramendy ML, Bohling T, Serra M, Hattinger CM, Kivioja A,
Elomaa I, Picci P, Knuutila S: Malignant fibrous histiocytoma of bone:
analysis of genomic imbalance by comparative genomic hybridization
Nishio et al. Journal of Experimental & Clinical Cancer Research 2010, 29:153
http://www.jeccr.com/content/29/1/153
Page 9 of 10and C-MYC expression by immunohistochemistry. Eur J Cancer 2006,
42:1172-1180.
32. Cho YL, Bae S, Koo MS, Kim KM, Chun HJ, Kim CK, Ro DY, Kim JH, Lee CH,
Kim YW, Ahn WS: Array comparative genomic hybridization analysis of
uterine leiomyosarcoma. Gynecol Oncol 2005, 99:545-551.
33. Artavanis-Tsakonas S, Matsuno K, Fortini ME: Notch signaling. Science 1995,
268:225-232.
34. Engin F, Bertin T, Ma O, Jiang MM, Wang L, Sutton RE, Donehower LA,
Lee B: Notch signaling contributes to the pathogenesis of human
osteosarcomas. Hum Mol Genet 2009, 18:1464-1470.
35. Franchi A, Santucci M: Tenascin expression in cutaneous fibrohistiocytic
tumors. Immunohistochemical investigation of 24 cases. Am J
Dermatopathol 1996, 18:454-459.
36. Kim WY, Sharpless NE: The regulation of INK4/ARF in cancer and aging.
Cell 2006, 127:265-275.
37. Simons A, Schepens M, Jeuken J, Sprenger S, van de Zande G,
Bjerkehagen B, Forus A, Weibolt V, Molenaar I, van de Berg E, Myklebost O,
Bridge J, van Kessel AG, Suijkerbuijk R: Frequent loss of 9p21 (p16
INK4A)
and other genomic imbalances in human malignant fibrous
histiocytoma. Cancer Genet Cytogenet 2000, 118:89-98.
doi:10.1186/1756-9966-29-153
Cite this article as: Nishio et al.: Establishment of a new human
pleomorphic malignant fibrous histiocytoma cell line, FU-MFH-2:
molecular cytogenetic characterization by multicolor fluorescence in situ
hybridization and comparative genomic hybridization. Journal of
Experimental & Clinical Cancer Research 2010 29:153.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Nishio et al. Journal of Experimental & Clinical Cancer Research 2010, 29:153
http://www.jeccr.com/content/29/1/153
Page 10 of 10